This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Valeant Pharmaceuticals: Eroded Reputation and Stock Price
Mary Gillett; Amy HorrocksCase IVEY-9B20B014-EAccounting and ControlIn early January 2019, a recent Ivey Business School graduate logged into her online trading account to review her portfolio’s performance. As she scanned her investments, she paused at one stock in particular. It was time to make a decision regarding one of her most volatile stocks—Valeant Pharmaceuticals International Inc., recently renamed Bausch Health Companies Inc. The pharmaceutical company was once celebrated for its innovative business a...Starting at €8.20
-
Sink or Float: An Oliver Wyman and Duke Royalty Investment Opportunity - Teaching Note
Mary Gillett; Amy HorrocksTeaching Note IVEY-8B18B005-EAccounting and ControlTeaching Note for product 9B18B005.Starting at €0.00
-
Sink or Float: An Oliver Wyman and Duke Royalty Investment Opportunity
Mary Gillett; Amy HorrocksCase IVEY-9B18B005-EAccounting and Control, StrategyIn late 2016, an analyst at Oliver Wyman (OW), was contemplating the high stakes of her new project. European riverboat company Temarca Group (Temarca) had just approached Duke Royalty (Duke) seeking €9.0 million to expand its riverboat fleet at the time. The analyst had to consider the first potential investment for the newly-formed partnership. If a financing decision was made, Temarca would be one of the first investments in Duke’s portfolio. ...Starting at €8.20